IDEXX Laboratories, Inc.
IDXX
Positions held
Your positionsIDXX isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-07.
- IDEXX Laboratories operates in the growing diagnostics and research industry, which is essential for veterinary and human health, providing a strong competitive edge.
- Revenue increased by 7% compared to the prior quarter, reaching $1.2 billion.
- Gross margin improved to 64% from 63.4% in the previous quarter.
- The company's current score indicates a 'Sell' signal, reflecting potential concerns about market performance.
- The stock has a trailing P/E ratio of 37.03, suggesting it may be overvalued compared to industry peers.
- The stock's 52-week high is $769.98, while it has recently shown a downward trend with a score of -12.00.
Fundamentals
| Market cap | $40.43B | Enterprise value | $41.32B | Trailing P/E | 36.06 | Forward P/E | 30.66 |
| PEG | 2.77 | Price / book | 25.10 | Beta | 1.55 | Dividend yield | 0.00% |
| Revenue growth | 9.7% | Earnings growth | 17.6% | Gross margin | 62.4% | Operating margin | 35.0% |
| Profit margin | 25.0% | ROE | 74.2% | ROA | 27.1% | Debt / equity | 0.68 |
| Current ratio | 1.17 | Free cash flow | $909.37M | Analyst recommendation | buy | Mean target | $701.33 |
| 52w high | $769.98 | 52w low | $500.61 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $1.2B | $1.1B | $1.1B | $1.1B | $1.1B |
| Op margin | 35.0% | 31.8% | 28.9% | 32.1% | 33.6% |
| Net income | $338M | $278M | $248M | $275M | $294M |
| Gross margin | 64.0% | 63.4% | 60.3% | 61.8% | 62.6% |
| Gross profit | $779M | $723M | $658M | $683M | $695M |
| Operating income | $426M | $363M | $316M | $355M | $373M |
- Revenue +7% vs prior quarter ($1.2B vs $1.1B).
- Gross margin 64% (was 63.4% prior quarter).
- Operating margin expanded to 35%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $4.3B | $3.9B | $3.7B | $3.4B | — |
| Op margin | 31.6% | 29.0% | 30.0% | 26.7% | — |
| Net income | $1.1B | $888M | $845M | $679M | — |
| Gross margin | 61.8% | 61.0% | 59.8% | 59.5% | — |
| Gross profit | $2.7B | $2.4B | $2.2B | $2.0B | — |
| Operating income | $1.4B | $1.1B | $1.1B | $899M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-01 · IDEXX Laboratories to Release 2026 Third Quarter Financial Results
2026-09-30 · IDEXX Laboratories Acquires Veterinary AI Platform CoVetAI
2026-09-30 · Chicago Pacific Founders Pet Fund Announces Exit of CoVetAI Following Acquisition by IDEXX Laboratories
2026-09-23 · Should You Continue to Hold IDXX Stock in Your Portfolio?
2026-09-20 · IDEXX Laboratories Highlights Diagnostic Pipeline, Reaffirms Long-Term Growth Targets
2026-09-20 · IDEXX Highlights Diagnostics Growth Drivers, Cancer Testing at Morgan Stanley Conference
2026-09-19 · IDEXX (IDXX) Bets an AI Scribe Can Sell More Pet Diagnostics
2026-09-18 · IDEXX (IDXX) Stock Trades Below Fair Value Following Its 26% Slide
2026-09-17 · IDEXX Laboratories (IDXX) Could Be 29% Below Fair Value As Diagnostics Growth Stays In Focus
2026-09-17 · Sector Update: Healthcare Stocks Edge Higher Pre-Bell Thursday
2026-09-17 · IDEXX Stock Gains Following the Acquisition of CoVet
Price (daily)
Full chart · RSI · MACD · patterns